FibroGen Reports Fourth Quarter and Full Year 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
FibroGen (FGEN) PT Lowered to $79 at Stifel
February 28, 2018 6:27 AM ESTStifel lowered its price target on FibroGen (NASDAQ: FGEN) to $79.00 (from $80.00) while maintaining a Buy rating following Q4 results.
Analyst Alex Schwartz noted for chronic kidney disease (CKD) anemia with roxadustat, the company now guided topline data in the U.S. during 4Q18 and an NDA filing in 1H19.
... More